Patent · US Active

Methods of producing RPE cells

US12195757B2 · kind B2 · utility

0Cited by
2References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 22, 2023
Grant dateJan 14, 2025
Priority date
Expiry dateAug 22, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2533/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.